Copyright
©The Author(s) 2022.
World J Gastroenterol. Jul 14, 2022; 28(26): 3218-3231
Published online Jul 14, 2022. doi: 10.3748/wjg.v28.i26.3218
Published online Jul 14, 2022. doi: 10.3748/wjg.v28.i26.3218
Table 3 Post transplant outcomes
Total (n = 111) | BMI after ascites correction | P value | ||
Overweight or obese (n = 82) | Underweight or normal (n = 29) | |||
Biliary stricture, n (%) | 22 (19.8) | 16 (19.5) | 6 (20.7) | 0.97 |
Biliary leak, n (%) | 10 (9) | 7 (8.5) | 3 (10.3) | 1.0 |
Hepatic artery thrombosis, n (%) | 2 (1.8) | 0 (0) | 2 (6.9) | 0.07 |
90-d re-hospitalization (n = 103), n (%) | 23 (22.3) | 17 (22.6) | 6 (21.4) | 0.89 |
Recurrent NAFLD, n (%) | 57 (51.4) | 44 (53.7) | 13 (44.8) | 0.59 |
Time to recurrent NAFLD, median (range) days | 568 (13–2135) | 489 (13–1821) | 757 (80–2135) | 0.21 |
Recurrent NASH, n (%) | 7 (6.3) | 5 (6.1) | 2 (6.9) | 1.0 |
Time to recurrent NASH, median (range) days | 812 (363–1119) | 802 (363–1119) | 957.5 (812–1103) | 0.28 |
BMI at 1 yr (n = 83), median (range) kg/m2 | 30.3 (19.2–44.0) | 31.7 (23.2–44.0) | 26.1 (19.2–34.2) | < 0.001c |
BMI at 5 yr (n = 17), median (range) kg/m2 | 33.9 (20.3–47.9) | 35.1 (26.6 – 47.9) | 27.0 (20.3–31.5) | 0.004b |
Creatinine at 1 yr (n = 70), median (range) μmol/L | 114.0 (54.0–279.0) | 117.5 (63.0–279.0) | 106.0 (54.0–178.0) | 0.21 |
Creatinine at 5 yr (n = 19), median (range) μmol/L | 143.0 (67.0-257.0) | 153.5 (78.0–257.0) | 111.0 (67.0–127.0) | 0.019a |
Diabetes at 1 yr (n = 82), n (%) | 36 (43.9) | 27 (45.8) | 9 (39.1) | 0.59 |
Diabetes at 5 yr (n = 20), n (%) | 10 (50) | 8 (53.3) | 2 (40) | 0.72 |
Hypertension at 1 yr (n = 83), n (%) | 44 (53) | 33 (55) | 11 (47.8) | 0.56 |
Hypertension at 5 yr (n = 20), n (%) | 12 (60) | 10 (66.7) | 2 (40) | 0.35 |
Cardiovascular events post LT, n (%) | 22 (19.8) | 14 (17) | 8 (27.6) | 0.45 |
Fibroscan Elastography (n = 48), median (range) kPa | 6.4 (2.3–21.8) | 6.8 (3.5–21.8) | 4.8 (2.3–14.5) | 0.011a |
Fibroscan CAP (n = 48), median (range) dB/m | 286.5 (181.0–400.0) | 298.0 (198.0–400.0) | 283.5 (181.0–400.0) | 0.26 |
Graft loss within 90 d post LT, n (%) | 5 (4.5) | 1 (1.2) | 4 (13.8) | 0.032a |
Graft survival post LT 1 yr (n = 101), n (%) | 94 (93.1) | 72 (98.6) | 22 (78.6) | 0.002b |
Graft survival post LT 3 yr (n = 72), n (%) | 65 (90.3) | 48 (96) | 17 (77.3) | 0.025a |
Graft survival post LT 5 yr (n = 32), n (%) | 22 (68.8) | 17 (85) | 5 (41.7) | 0.018a |
Deaths post LT, n (%) | 7 (6.3) | 2 (2.4) | 5 (17.2) | 0.029a |
Time to death post LT (n = 7), median (range) days | 224 (13–1176) | 192.5 (20–365) | 224 (13–1176) | 0.42 |
Death within 90 d post-LT, n (%) | 2 (1.8) | 1 (1.2) | 1 (3.4) | 0.38 |
Patient survival at 1 yr (n = 108), n (%) | 104 (96.3) | 78 (98.7) | 26 (89.7) | 0.06 |
Patient survival at 3 yr (n = 97), n (%) | 66 (91.7) | 48 (96) | 18 (81.8) | 0.07 |
Patient survival at 5 yr (n = 32), n (%) | 25 (78.1) | 18 (90) | 7 (58.3) | 0.07 |
- Citation: Qazi-Arisar FA, Uchila R, Chen C, Yang C, Chen SY, Karnam RS, Azhie A, Xu W, Galvin Z, Selzner N, Lilly L, Bhat M. Divergent trajectories of lean vs obese non-alcoholic steatohepatitis patients from listing to post-transplant: A retrospective cohort study. World J Gastroenterol 2022; 28(26): 3218-3231
- URL: https://www.wjgnet.com/1007-9327/full/v28/i26/3218.htm
- DOI: https://dx.doi.org/10.3748/wjg.v28.i26.3218